BCAL Diagnostics Ltd (ASX: BDX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

BCAL Diagnostics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $27.75 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 252.29 million
Earnings per share -0.023
Dividend per share N/A
Year To Date Return 11.11%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • BCAL Diagnostics Ltd (ASX: BDX)
    Latest News

    four excited doctors with their hands in the air
    Healthcare Shares

    'Breakthrough results': Why this ASX healthcare share just exploded 160%

    BCAL Diagnostics has developed a blood test to detect breast cancer that it says may be ready for commercialisation within…

    Read more »

    three excited doctors with hands in the air
    Healthcare Shares

    3 ASX health care shares that outpaced the market on Friday

    These three healthcare shares had a better day than the broader index.

    Read more »

    BDX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About BCAL Diagnostics Ltd

    BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.

    BDX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    12 Jun 2024 $0.12 $0.01 9.09% 1,240,625 $0.12 $0.12 $0.11
    11 Jun 2024 $0.11 $-0.02 -16.00% 1,315,916 $0.12 $0.13 $0.11
    07 Jun 2024 $0.13 $0.00 0.00% 1,436,890 $0.13 $0.13 $0.12
    06 Jun 2024 $0.13 $-0.02 -14.29% 608,703 $0.14 $0.14 $0.13
    05 Jun 2024 $0.14 $0.02 16.00% 287,818 $0.13 $0.14 $0.13
    04 Jun 2024 $0.13 $-0.02 -13.79% 1,383,665 $0.14 $0.14 $0.13
    03 Jun 2024 $0.15 $-0.03 -17.14% 2,118,785 $0.14 $0.16 $0.13
    29 May 2024 $0.18 $0.04 28.57% 1,313,844 $0.15 $0.19 $0.14
    28 May 2024 $0.14 $0.02 16.67% 837,228 $0.12 $0.15 $0.12
    27 May 2024 $0.12 $0.01 9.09% 355,227 $0.12 $0.12 $0.11
    24 May 2024 $0.11 $-0.01 -8.70% 71,299 $0.11 $0.11 $0.11
    22 May 2024 $0.12 $0.00 0.00% 63,487 $0.12 $0.12 $0.11
    21 May 2024 $0.12 $0.00 0.00% 66,982 $0.12 $0.12 $0.11
    20 May 2024 $0.12 $0.01 9.52% 60,768 $0.12 $0.12 $0.11
    17 May 2024 $0.11 $-0.01 -9.09% 198,925 $0.11 $0.12 $0.11
    16 May 2024 $0.11 $-0.01 -8.70% 180,859 $0.12 $0.12 $0.11
    15 May 2024 $0.12 $0.00 0.00% 165,367 $0.12 $0.12 $0.12
    14 May 2024 $0.12 $0.02 20.00% 747,803 $0.11 $0.13 $0.11

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    24 Nov 2023 Mark Burrows Issued 300,000 $30,000
    Placement.
    24 Nov 2023 Jonathan Trollip Issued 200,000 $20,000
    Placement.
    23 Nov 2023 Ronald (Ron) Phillips Exercise 2,022,638 $116,099
    Exercise of options.
    23 Nov 2023 Ronald (Ron) Phillips Buy 2,022,638 $116,099
    Exercise of options.
    23 Nov 2023 Jonathan Trollip Buy 1,155,793 $66,343
    Exercise of options.
    23 Nov 2023 Jonathan Trollip Exercise 1,155,793 $66,343
    Exercise of options.
    23 Nov 2023 Jayne Shaw Exercise 2,022,638 $116,099
    Exercise of options.
    23 Nov 2023 Jayne Shaw Buy 2,022,638 $116,099
    Exercise of options.
    18 Sep 2023 Merilyn Sleigh Buy 200,000 $20,000
    Participation in share purchase plan.
    18 Sep 2023 Jonathan Trollip Buy 300,000 $30,000
    Participation in share purchase plan.
    18 Sep 2023 Jayne Shaw Buy 300,000 $30,000
    Participation in share purchase plan.
    18 Sep 2023 Ronald (Ron) Phillips Buy 157,746 $15,774
    Participation in share purchase plan.
    18 Sep 2023 Ronald (Ron) Phillips Buy 142,254 $14,225
    Participation in share purchase plan.
    18 Sep 2023 Mark Burrows Buy 300,000 $30,000
    Participation in share purchase plan.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Mark Douglas Irving Burrows Non-Executive Director Jul 2021
    Mr Burrows is an advocate for early diagnosis of breast cancer and other cancers. He has enjoyed a long and distinguished career in investment banking both in Australia and the UK. Mr. Burrows cofounded Baring Brothers Burrows & Co in Australia in the early 80s. In 1999 he was appointed the Managing Director/Deputy Chairman of ING Barings in London. In 2004, Mark joined Lazard as a Managing Partner and in 2006 returned to Australia and was appointed Lazard Australia's inaugural Chairman. Mr. Burrows returned to investment banking in 2011 as Vice Chairman of Credit Suisse's Global Investment Bank. During his investment banking career, Mr. Burrows has been the principal financial advisor to some of the corporate and government transactions in Australia. Mr Burrows is a member of Risk Management Committee.
    Mr David George Darling Non-Executive Director Mar 2024
    Mr Darling is a executive who brings a commercial experience to BCAL from his prior role as CEO of Pacific Edge, a NZX50 and ASX listed business on commercialising its bladder cancer diagnostics tests across global markets, with commercial operations in New Zealand, Australia, Singapore and the USA. Prior to Pacific Edge, Mr Darling held senior management positions with Fletcher Challenge. Mr Darling has a background as a scientist with a specialty in genetics and has more than three decades of experience in developing and commercialising life sciences and biotechnology products. Mr Darling also brings a of governance and executive management experience having served as a director of Pacific Edge nd its subsidiary businesses in New Zealand, Australia, Singapore and the USA. He is also is a board director on a number of private business and organisation boards.
    Ms Jayne Andrea Shaw Executive ChairmanExecutive Director Feb 2010
    Ms Shaw is Trained as a Registered Nurse in the UK, on arrival in Australia Jayne became a Director of Nursing and Chief Executive Officer of two private hospitals. Following this, she established an Australian and international consulting business which was sold to Healthsouth a US Healthcare company. Ms Shaw has been a member of a number of private healthcare boards involved with specialist consolidation including cardiology, orthopaedics, and women's health, and continued to work with private equity firms on local and International Healthcare transactions.
    Dr John Hurrell Non-Executive Director Feb 2022
    Dr Hurrell has developed and commercialized multiple products and services in life sciences and diagnostics over a career in the industry spanning more than 35 years. He has developed and managed start-up and early-stage companies including successful life science companies based on university developed technologies. Dr Hurrell spent almost 7 years in managerial and executive roles with NYSE-listed, Fortune 500 clinical laboratory company Quest Diagnostics. Within Quest's subsidiary Focus Diagnostics, he led the development and launch of more than 70 molecular diagnostics tests and gained approvals for 6 products. He also served as VP of Business Development at Quest Diagnostics. Most recently, he was Chief Commercial Officer at JanaCare, a remote chronic disease patient management company with a focus on diabetes and kidney disease. Other previous roles include President of the Asia/Pacific region and Head of International Sales for PTS Diagnostics, a diabetes and wellness company based in Indiana, USA, and Senior Executive Vice President International Business for Seegene Inc., a multinational molecular diagnostics company focusing on infectious disease, based in Seoul, South Korea.
    Mr Jonathan Alfred Grey Trollip Non-Executive Director Dec 2020
    Mr Trollip is a experienced professional non-executive Director with over 30 years of commercial, corporate, governance and legal and transactional expertise. Mr Trollip was previously a director of Propel Funeral Partners Limited (19/9/2017 to 6/5/2022) and Yellow Holdings Limited (5/12/2019 to 1/4/2023). He has a interest in the not-for-profit sector and is involved at Board level and a contributor with various not for profit organisations in Australia and Southern Africa in the education sector and in wildlife conservation. Mr Trollip is the Chair of Risk Management Committee.
    Hon Ronald (Ron) Anthony Phillips Non-Executive Director Feb 2010
    Mr Phillips has 15 years in the NSW Parliament which included serving as Minister for Health and Deputy Leader of the Opposition, Mr Phillips developed a consulting business in the Health and Aged Care Industry. His business interests included co-owner and Managing Director of Sydney Breast Clinic which he sold to Healthscope. He recently retired as Chair of the Sydney Local Health District and as Director of Westmead IVF. Mr Phillips has had no other listed entity directorships in the last three years. He is Member of Risk Management Committee
    Mr Guy Adrian Robertson Chief Financial OfficerCompany Secretary
    -
    Mr Shane Ryan Chief Executive Officer Apr 2024
    -
    Shane Ryan Chief Executive Officer
    -
    Guy Adrian Robertson Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Nabelle Pty Ltd <The Shaw Super Fund A/C> 19,162,405 7.97%
    Ann-Marie Phillips 16,574,988 6.90%
    Capital Property Corporation Pty Ltd <Carrington A/C> 15,193,425 6.32%
    Mera Vale No 1 Pty Ltd <Mera Vale No 1 A/C> 11,593,215 4.82%
    The Trust Company (Australia) Limited <Mbf A/C> 11,400,000 4.74%
    Ronald Anthony Phillips 8,260,604 3.44%
    The Trust Company (Australia) Limited <Mof A/C> 7,830,298 3.26%
    Coolbrun Pty Ltd <The Coolbrun Family A/C> 6,633,789 2.76%
    Nabelle Pty Ltd <The Shaw Family A/C> 6,115,172 2.54%
    Carwoola Pastoral Co Pty Ltd 4,424,895 1.84%
    John Hurrell 4,200,000 1.75%
    Angelo Korsanos & Antonia Korsanos <Korsanos Family A/C> 3,484,050 1.45%
    Vintage Dawn Pty Ltd <Jamie + Caroline Odell S/F> 3,484,050 1.45%
    Piaster Pty Ltd <Trollip Family S/F A/C> 3,447,649 1.43%
    Citicorp Nominees Pty Limited 3,378,611 1.41%
    Sean Kennedy 3,300,303 1.37%
    Mera Vale No 1 Pty Ltd II<Mera Vale No 1 A/C> 3,200,000 1.33%
    Darville Pty Limited 3,101,660 1.29%
    Scapa Pty Ltd <The Scapa A/C> 3,048,563 1.27%
    Innovative Management Pty Ltd <Thn Family Office A/C> 3,000,000 1.25%
    Logitix Pty Ltd <Smith Family A/C> 2,742,025 1.14%

    Profile

    since

    Note